Fanapt Sanctioned for Schizophrenia

But FDA warns against off-label use

May 7, 2009 RSS Feed Print

THURSDAY, May 7 (HealthDay News) -- A new pill to treat adults with schizophrenia has been approved by the U.S. Food and Drug Administration.

Fanapt (iloperidone), which belongs to the atypical antipsychotic class of drugs, is not approved for patients with dementia-related psychosis, United Press International reported.

The FDA ordered that Fanapt carry a boxed warning about the increased risk of death associated with off-label use of the drug to treat behavioral problems in patients with dementia-related psychosis.

Fanapt is made by Patheon Inc., in Ontario, Canada, for Vanda Pharmaceuticals Inc., of Rockville, Md., UPI reported.

More information

The FDA has more about this approval.

Copyright © 2011 HealthDay. All rights reserved.

Tags:
FDA,
drugs,
schizophrenia

Reader Comments

Add Your Thoughts
Your comment will be posted immediately, unless it is spam or contains profanity. For more information, please see our Comments FAQ.

advertisement

U.S. News Rankings & Research

U.S. News's "Best" delivers recognized, authoritative information and clear, objective rankings that help readers plan for their life and ultimately, make the most of it.

Featured Videos

Depression

Learn how to recognize the symptoms.

Suffering from Migraines?

Know your triggers to prevent a migraine meltdown.

Rheumatoid Arthritis

Rheumatoid Arthritis can affect the young and old alike.

advertisement